Median Duration of Response (DOR) Not Reached at 33.1 Months of Median Study Follow Up in Cohort 2 in C-144-01 Study
Early Intervention with Lifileucel Following Progression on Anti-PD-1 Therapy May Maximize Benefit
ASCO Update Conference Call and Webcast at 12 p.m. ET Today
SAN CARLOS, Calif., June 06, 2021 (GLOBE NEWSWIRE) — Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced updated clinical data for lifileucel from Cohort 2 in the C-144-01 clinical study in patients with advanced melanoma. The data were presented in an oral presentation at the ASCO 2021 Annual Meeting.
Omid Hamid, M.D., Chief of Research/Immuno-Oncology, The Angeles Clinic & Research Institute, stated, “Anti-PD-1 therapy is a mainstay class of treatment offering...